welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03532542
condition: Duchenne Muscular Dystrophy
status: enrolling by invitationpurpose:
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
intervention: Casimersen, Golodirsen
mechanism of action: Exon-skipping to promote dystrophin production
last updated: February 26, 2019
start date: August 2, 2018
estimated completion: June 30, 2026
phase of development: Phase 3
size / enrollment: 260
- Number of patients with serious adverse events (SAEs) [Time Frame: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)]]
• Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
• Is between 7 and 23 years of age, inclusive, at enrollment.
Study of ataluren in previously treated participants with nonsense mutation dystrophinopathy (nmDBMD)The objective of this study is to assess...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular DystrophyDystrophinopathy is a disease continuum ...
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug ApplicationOn February 14, 2019, Sarepta Therapeuti...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...